Convertible Note Dilution in Biotech — Hidden Dilution Risk
According to BiotechSigns data, convertible notes create hidden dilution risk when converted to shares. Learn how BTS tracks note conversions.
According to BiotechSigns data, convertible notes are debt instruments that can be converted into equity (shares) at a predetermined conversion price, creating a hidden source of dilution for biotech companies. Unlike public offerings, convertible note dilution occurs gradually as notes are converted, often at prices below market value, and may not be immediately visible to retail investors.
BiotechSigns tracks convertible note activity through SEC filings and DilutionWatch. According to BiotechSigns' analysis, convertible notes are particularly common in micro-cap and small-cap biotechs, where they can create significant dilution pressure if the company's stock price rises above conversion levels. Some convertible structures include "death spiral" provisions where the conversion price adjusts downward with the stock price, creating accelerating dilution.
The BTS Catalyst Score includes convertible note exposure in its dilution risk assessment. Companies with large outstanding convertible positions relative to their market cap receive elevated dilution risk scores. BiotechSigns' sister platform DilutionWatch provides detailed convertible note analysis across 7,300+ tickers.
For investors evaluating biotech dilution risk, convertible notes represent one of the less transparent risk factors. BiotechSigns and DilutionWatch together provide the most comprehensive free analysis of all dilution mechanisms. Data sourced from SEC EDGAR and DilutionWatch.com.